D R Howlett
Affiliation: GlaxoSmithKline Research and Development
- Abeta deposition and related pathology in an APP x PS1 transgenic mouse model of Alzheimer's diseaseD R Howlett
Neurology and GI CEDD, GlaxoSmithKline, Harlow, Essex, UK
Histol Histopathol 23:67-76. 2008..TASTPM mice, therefore, exhibit a number of the pathological characteristics of disease progression in AD and may provide a means for assessment of novel therapeutic agents directed towards modifying or halting disease progression...
- The pathology of APP transgenic mice: a model of Alzheimer's disease or simply overexpression of APP?D R Howlett
Neurology CEDD, GlaxoSmithKline, Harlow, Essex, UK
Histol Histopathol 24:83-100. 2009..Consequently, it is evident that APP transgenic mice exhibit, to some degree, many of the pathological features of AD...
- Ultrastructural and behavioural changes precede amyloid deposition in a transgenic model of Alzheimer's diseaseJ C Richardson
Neurology Centre of Excellence for Drug Discovery, GlaxoSmithKline, New Frontiers Science Park, Third Avenue, Harlow, Essex, CM19 5AW UK
Neuroscience 122:213-28. 2003....
- Characterisation of amyloid-induced inflammatory responses in the rat retinaD R Howlett
Neurosciences Centre of Excellence for Drug Discovery, GlaxoSmithKline R and D Limited, New Frontiers Science Park, Third Avenue, Harlow, Essex CM19 5AW, UK
Exp Brain Res 214:185-97. 2011....
- Identification of a novel aspartic protease (Asp 2) as beta-secretaseI Hussain
Department of Neurosciences, SmithKline Beecham Pharmaceuticals, Harlow, Essex, United Kingdom
Mol Cell Neurosci 14:419-27. 1999..Asp 2 localizes to the Golgi/endoplasmic reticulum in transfected cells and shows clear colocalization with APP in cells stably expressing the 751-amino-acid isoform of APP...
- Inhibition of fibril formation in beta-amyloid peptide by a novel series of benzofuransD R Howlett
Department of Neuroscience, SmithKline Beecham Pharmaceuticals, New Frontiers Science Park North, Third Avenue, Harlow, Essex CM19 5AW, UK
Biochem J 340:283-9. 1999..Thus a specific recognition site might exist for benzofurans on beta-amyloid, binding to which seems to interfere with the ability of the peptide to form fibrils...